Covetrus

Traded on the St. Petersburg Stock Exchange
Covetrus is a global animal-health company dedicated to empowering veterinary practices.
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Covetrus balance sheet

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Covetrus cash flows

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Covetrus multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

Covetrus profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Covetrus assets
Covetrus cash flows
Covetrus news
25.05.2022
CD&R and asset management company TPG Capital will acquire all outstanding shares of Covetrus. CD&R and its affiliates currently own 24% of the stock. The deal is expected to close in the second half of 2022. The amount will be $4 billion, or $21 per share.
06.05.2022
The loss of Covetrus under GAAP for the 3 months of 2022 was $2 million, down 8 times from $16 million in the previous year. Revenue increased 4.2% to $1.148 billion from $1.102 billion a year earlier.
25.02.2022
Covetrus' GAAP loss for 2021 was $54 million, up 3.2 times from $17 million in the previous year. Revenue increased 5.4% to $4.575 billion from $4.339 billion a year earlier.
05.11.2021
Covetrus reported a GAAP loss of $51 million for 9M 2021, up 3.6x from $14 million in the previous year. Revenue increased by 7.3% to $3.453 billion from $3.217 billion a year earlier.